Orchestra Bio builds an agentic operations platform for drug development. Founded in 2022, the company develops software that helps life sciences R&D organisations unify planning, automate operations and connect science, operations and finance within a single intelligent platform. The stated aim is to support the journey from discovery to medicine and to help R&D organisations make every R&D dollar count.
The company emerged from stealth with $20 million in financing, backed by investors including 8VC, Andreessen Horowitz, Insight Partners, Definition and Haystack. The founding team is drawn from early leaders at Benchling, and the company's work sits at the intersection of enterprise software and R&D management in life sciences.
Technical domains relevant to the company's work include agentic AI, R&D operations software, planning automation, enterprise software and life sciences informatics. The industries it serves span biotechnology, life sciences, pharmaceutical R&D and drug development more broadly.
Orchestra Bio describes its mission as helping breakthrough science reach patients, with an emphasis on bringing software and agile practices to R&D management.
